FUSION PHARMACEUTICALS
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)β’ Click on a phase to view related trials
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT06909825
- Locations
- π¦πΊ
Macquarie University Hospital, Macquarie Park, New South Wales, Australia
π¦πΊPrincess Alexandra Hospital, Woolloongabba, Queensland, Australia
π¦πΊIcon Cancer Centre Kurralta Park, Kurralta Park, South Australia, Australia
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06402331
- Locations
- πΊπΈ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈHoag Health Center Irvine, Irvine, California, United States
πΊπΈVA Greater Los Angeles Healthcare System, Los Angeles, California, United States
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
- Conditions
- Advanced Solid TumorMetastatic Colorectal CarcinomaHead and Neck Squamous Cell CarcinomaNon-small Cell Lung CancerPancreatic Ductal AdenocarcinomaGastric CancerRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT06147037
- Locations
- πΊπΈ
Hoag Hospital, Irvine, California, United States
πΊπΈUCLA Medical Center, Santa Monica, California, United States
πΊπΈStanford Hospital and Clinics, Stanford, California, United States
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
- Conditions
- Bladder CarcinomaHead and Neck Squamous Cell CarcinomaSusceptible FGFR3 Genetic AlterationsBreast CancerFGFR3 ReceptorFGFR3 Protein OverexpressionColorectal CancerLiver CancerAdvanced Solid TumorFGFR3
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05363605
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΊπΈUniversity of California, San Francisco, San Francisco, California, United States
πΊπΈUniversity of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT05219500
- Locations
- πΊπΈ
XCancer Omaha/Urology Cancer Center, Omaha, Nebraska, United States
πΊπΈExcel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
- Prev
- 1
- 2
- Next
News
Radiopharmaceuticals: The Next Frontier in Precision Oncology as Big Pharma Competes for Market Share
Radiopharmaceuticals are emerging as a powerful precision medicine approach in oncology, with Novartis leading the market through FDA-approved therapies Lutathera and Pluvicto generating over $2.1 billion in 2024.
Biopharma M&A Activity Reaches $79.4 Billion in 2024 Despite 50% Drop from Previous Year
Biopharma M&A activity totaled $79.4 billion in 2024, representing approximately half of 2023's total value, though deal volume saw a slight increase when excluding four mega-deals from the previous year.
Pharmaceutical R&D Highlights of 2024: GLP-1s, CRISPR, and More
β’ GLP-1 receptor agonists like semaglutide and tirzepatide showed potential beyond diabetes and weight loss, including cardiovascular and mental health benefits. β’ CRISPR gene editing entered the market with Casgevy for sickle cell disease and Ξ²-thalassemia, though uptake has been slow due to complex treatment requirements. β’ Protein-folding algorithms developed by Nobel laureates revolutionized biochemical research and found applications in pharmaceutical drug discovery. β’ Antibody-drug conjugates (ADCs) saw major investment, with firms focusing on novel linker chemistries to enhance their efficacy and target specificity.